Biotech M&A in 2026 already surpasses all of 2025

Biotech dealmaking has reached a "torrid pace" in 2026, with more transactions exceeding $1 billion already completed this year than in all of 2025 combined, according to Krishna Veeraraghavan, global co-head of M&A at Paul Weiss, who discussed the trend on Bloomberg Television on Tuesday.bloomberg+1

The surge in life sciences M&A has positioned 2026 as the strongest year for biopharma deals since before the pandemic, fueled by patent expirations, revitalized public markets, and pharmaceutical companies' urgency to replenish their pipelines.

A Boom Beyond Blockbusters

The deal frenzy extends well beyond the mega-mergers that typically dominate headlines. Mid-cap companies are now stepping up as acquirers, pursuing targets valued at $1 billion to $2 billion — a segment that was largely the domain of big pharma in prior years. Private market deal volumes have also climbed sharply, according to Veeraraghavan's Bloomberg appearance.endpoints+3

Data from STAT News reported that the first six months of 2026 saw $134 billion in deals, surpassing last year's full-year total of $112 billion, with 33 biotech acquisitions worth at least $1 billion. PwC's midyear outlook noted that deal value topped $65 billion in the first quarter alone, with 16 deals exceeding $1 billion announced in that period.pwc+2

Drivers of the Surge

The most persistent force behind the wave remains the so-called patent cliff. Major pharmaceutical companies face over $230 billion in revenue at risk from loss of exclusivity by 2030, compelling them to acquire innovative assets in oncology, immunology, cardiometabolic diseases, and rare diseases.linkedin+1

RBC Capital Markets noted that in the second half of 2025 and first half of 2026, 33 deals worth $1 billion or more were completed — triple the number in the four preceding quarters. Ernst & Young counted $100 billion in capital deployed in deals in 2025, with the pace accelerating to $36 billion in the first quarter of 2026 alone.rbccm+1

Outlook for the Rest of the Year

Should current momentum persist, CNBC reported the sector could exceed $250 billion in total deal value for the year, which would represent the highest level since 2019. The average deal size has risen to $527 million in 2026, up from $365 million in 2025. With buyers diversifying beyond traditional big pharma and capital flowing into both public and private biotech markets, dealmakers expect the second half of the year to remain active.cnbc